E2F3
Transcription factor E2F3
As of the edition of 20 October 2026, E2F3 (transcription factor E2F3, UniProt O00716) has 2 drugs tested at it and 0 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O00716
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Inside the cell
- Disease areas
- Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 3
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Edifoligide sodium | Went quiet | Phase 3 | none listed |
| Edifoligide | Stopped | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Total on the list | 0 |